Ocugen (OCGN) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Company Participants Tiffany Hamilton - AVP & Head of Corporate CommunicationsShankar Musunuri - Co-Founder, CEO & ChairmanRamesh Ramachandran - Chief Accounting OfficerHuma Qamar - Chief Medical OfficerArun Upadhyay - Chief Scientific Officer and Head of Research & Development Conference Call Participants Michael Okunewitch - Senior Biotechnology AnalystRobert Leboyer - Senior Biotechnology AnalystSwayampakula Ramakanth - Managing Director & Seni ...

Ocugen (OCGN) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Company Participants Tiffany Hamilton - AVP & Head of Corporate CommunicationsShankar Musunuri - Co-Founder, CEO & ChairmanRamesh Ramachandran - Chief Accounting OfficerHuma Qamar - Chief Medical OfficerArun Upadhyay - Chief Scientific Officer and Head of Research & Development Conference Call Participants Michael Okunewitch - Senior Biotechnology AnalystRobert Leboyer - Senior Biotechnology AnalystSwayampakula Ramakanth - Managing Director & Seni ...

Ocugen (OCGN) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Speaker0 Good morning, and welcome to Ocugen's First Quarter twenty twenty five Financial Results and Business Update. Please note that this call is being recorded at this time. All participant lines are in listen only mode. Following the speakers' commentary, there will be a question and answer session. I will now turn the call over to Tiffany Hamilton, Ocugen's Head of Corporate Communications. You may begin. Speaker1 Thank you, operator, and go ...

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financia ...

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atr ...